{"nctId":"NCT00766493","briefTitle":"GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)","startDateStruct":{"date":"2009-01"},"conditions":["Carotid Artery Stenosis"],"count":250,"armGroups":[{"label":"GORE® Embolic Filter","type":"EXPERIMENTAL","interventionNames":["Device: GORE® Embolic Filter"]}],"interventions":[{"name":"GORE® Embolic Filter","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is either:\n\n   * Symptomatic (amaurosis fugax in the hemisphere supplied by the target vessel, TIA or non-disabling stroke within 6 months of the procedure) with carotid stenosis ≥50% as diagnosed by angiography using NASCET methodology, OR\n   * Asymptomatic with carotid stenosis ≥80% as diagnosed by angiography using NASCET methodology\n2. Target lesion is located in one of the following:\n\n   * ICA\n   * bifurcation\n   * CCA proximal to the bifurcation\n3. At Anatomic risk for adverse events from CEA (e.g., restenosis after a prior CEA) or at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)\n\nExclusion Criteria:\n\n* Recent surgical procedure within 30 days before or after the stent procedure\n* Uncontrolled sensitivity to contrast media\n* Renal Insufficiency\n* Recent evolving, acute stroke within 21 days of study evaluation\n* Myocardial infarction within 72 hours prior to stent procedure\n* History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)\n* Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)\n\nAngiographic Exclusion Criteria:\n\n* Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow\n* Total occlusion of the ipsilateral carotid artery\n* Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch\n* Presence of a filling defect, thrombus, occlusion or \"string sign\" in the target vessel\n* Severe lesion calcification restricting stent deployment\n* Carotid stenosis located distal to target stenosis that is more severe than target stenosis\n* \\>50% stenosis of the CCA proximal to target vessel\n* Known mobile plaque in the aortic arch","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Major Adverse Event (MAE) Rate of Death, Myocardial Infarction, and Stroke at 30 Days Postprocedure","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Device Success","description":"Device Success defined as the number of participants with Technical Success using the GORE Embolic Protection System (i.e., the GORE Embolic Filter device was delivered, placed, and retrieved as outlined in the Instructions for Use).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success","description":"Clinical Success defined as GORE Embolic Filter and carotid stent success in the absence of death, emergency endarterectomy, repeat PTA / thrombolysis of the target vessel, and stroke or MI as determined by the Clinical Events Committee. Clinical success will be evaluated from procedure through 24-48 hours postprocedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null}]}]}]},{"type":"SECONDARY","title":"Access Site Complications","description":"Access Site Complications defined as the presence of a large hematoma (\\>5cm or requiring treatment or prolonged hospitalization), fistula or pseudoaneurysm formation, retroperitoneal bleeding or the need for surgical repair postprocedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Neurologic Events","description":"Neurological Events at 30 days post-procedure, including transient ischemic attacks (TIAs).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":250},"commonTop":["Hypotension","Hypertension","Anemia","Nervous System - Other","Nausea"]}}}